Phaseline

Targets › MUC17

MUC17 (Mucin-17): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Mar 2027.

Probably plays a role in maintaining homeostasis on mucosal surfaces. (UniProt, Q685J3)

Open in Phaseline: the race on MUC17, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shenyang Sunshine PharmaceuticalSSS59
humanized antibody targeting MUC17
MUC17Phase 1Malignant TumorsMar 2027
Suzhou Zelgen BiopharmaceuticalsZGGS34
anti-MUC17 monoclonal antibody
MUC17Phase 1Solid TumorDec 2028

Conditions

Solid Tumor (1) Malignant Tumors (1)

Modalities

protein or peptide (1), small molecule (1)

Companies

Suzhou Zelgen Biopharmaceuticals (1) Shenyang Sunshine Pharmaceutical (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.